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Abstract
Background: Microglial activation is an important histologic characteristic of the pathology of Alzheimer’s disease
(AD). One hypothesis is that amyloid beta (Aβ) peptide serves as a specific stimulus for tyrosine kinase-based
microglial activation leading to pro-inflammatory changes that contribute to disease. Therefore, inhibiting Aβ
stimulation of microglia may prove to be an important therapeutic strategy for AD.
Methods: Primary murine microglia cultures and the murine microglia cell line, BV2, were used for stimulation with
fibrillar Aβ1-42. The non-receptor tyrosine kinase inhibitor, dasatinib, was used to treat the cells to determine
whether Src family kinase activity was required for the Aβ stimulated signaling response and subsequent increase in
TNFα secretion using Western blot analysis and enzyme-linked immunosorbent assay (ELISA), respectively. A
histologic longitudinal analysis was performed using an AD transgenic mouse model, APP/PS1, to determine an age
at which microglial protein tyrosine kinase levels increased in order to administer dasatinib via mini osmotic pump
diffusion. Effects of dasatinib administration on microglial and astroglial activation, protein phosphotyrosine levels,
active Src kinase levels, Aβ plaque deposition, and spatial working memory were assessed via
immunohistochemistry, Western blot, and T maze analysis.
Results: Aβ fibrils stimulated primary murine microglia via a tyrosine kinase pathway involving Src kinase that was
attenuated by dasatinib. Dasatinib administration to APP/PS1 mice decreased protein phosphotyrosine, active Src,
reactive microglia, and TNFα levels in the hippocampus and temporal cortex. The drug had no effect on GFAP
levels, Aβ plaque load, or the related tyrosine kinase, Lyn. These anti-inflammatory changes correlated with
improved performance on the T maze test in dasatinib infused animals compared to control animals.
Conclusions: These data suggest that amyloid dependent microgliosis may be Src kinase dependent in vitro and
in vivo. This study defines a role for Src kinase in the microgliosis characteristic of diseased brains and suggests that
particular tyrosine kinase inhibition may be a valid anti-inflammatory approach to disease. Dasatinib is an FDA-
approved drug for treating chronic myeloid leukemia cancer with a reported ability to cross the blood-brain barrier.
Therefore, this suggests a novel use for this drug as well as similar acting molecules.
Introduction
Amyloid beta deposition and microglial activation are
two major pathophysiologic hallmarks of the progression
of Alzheimer’s disease, often suggested to be associated
with each other [1-9]. Microglia are the resident phago-
cytes of the central nervous system. In the AD brain,
microglia are found in a highly activated state often in
association with senile plaques [10-13]. Activated micro-
glia present a different phenotype as compared to resting
microglia, and are responsible for, in particular, pro-in-
flammatory cytokine secretions [10-18]. Aβ accumula-
tion in AD has been associated with these increases in
pro-inflammatory markers [19-25]. Aβ peptide has the
ability to self-aggregate to form oligomers and fibrils.
Both forms have been reported to have neurotoxic and
gliotic actions in vitro as well as in vivo [24-36]. Because
of the close proximity of reactive microglia to deposited
fibrils of Aβ, it is hypothesized that Aβ acts as a stimulus
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propagate the inflammatory changes observed. There-
fore, there is a need to identify a therapeutically ap-
proachable microglial target for reducing inflammation
in the brains of AD patients. Based upon the fact that re-
cent data demonstrate that prolonged non-steroidal anti-
inflammatory drug use decreases incidence of AD when
taken by asymptomatic individuals, an anti-inflammatory
approach to disease may be an effective prevention strat-
egy [37]. It is imperative to understand the mechanism(s)
by which microglia become reactive to better design
anti-inflammatory drug strategies.
Although data suggest a causative role of Aβ depos-
ition for microgliosis, the underlying mechanisms
involved are not fully resolved [10,18,28,38-41]. It has
been demonstrated through a variety of studies that
Aβ is capable of stimulating microglia in vitro and
in vivo to increase protein phosphotyrosine levels.
This correlates well with the reported increase in
microglial phospho-tyrosine immunoreactivity in AD
brains [42]. These data have supported a hypothesis
that the increase in phosphotyrosine immunoreactivity
is due to either increased tyrosine kinase activity or
decreased tyrosine phosphatase activity. It appears that
both scenarios may be true. Microglia can use a
multi-receptor complex for interacting with Aβ fibrils
o nt h ep l a s m am e m b r a n e[ 4 3 ] .U p o nl i g a n db i n d i n g ,a
specific signaling pathway is activated involving propa-
gation and downstream increased activation of numer-
ous non-receptor tyrosine kinases, including Src, Lyn,
FAK and PYK2 [24,28,39,41,44-47]. Based upon inhib-
ition studies, the increased tyrosine kinase enzyme ac-
tivities upon Aβ binding are absolutely critical for
microgliosis to occur [24,28,39,41,44-47]. In fact, it
appears that not only increased tyrosine kinase activity
is required for Aβ stimulation but also decreased tyro-
sine phosphatase activity [48,49]. Our prior work
demonstrated that both oligomeric and fibrillar forms
of Aβ stimulate increased protein phosphotyrosine
levels in vitro and in vivo that correlated with activation
of non-receptor tyrosine kinases [38,50]. Irrespective of
the form of Aβ involved, one common mechanism of
action appears to be involvement of tyrosine kinases
leading to increased secretion of proinflammatory cyto-
kines. This study tests whether inhibition of the Aβ fi-
bril-stimulated signaling response, more precisely non-
receptor tyrosine kinase activity, can attenuate micro-
gliosis both in vitro and in vivo. The Src-Abl inhibitor,
dasatinib, was used to treat primary murine microglia
cultures in vitro. In order to quantify effects of dasati-
nib in a more physiologically relevant form of disease,
the drug was also administered to a transgenic mouse
model of AD. This APP/PS1 mouse line expresses a
Swedish mutation in APP and a deltaE9 mutation of
presenilin 1 (PS1). The mice over-express human Aβ
with a correlating high Aβ plaque immunoreactivity
and microgliosis [51,52].
In this work, we demonstrated using primary murine
microglia cultures that dasatinib was able to attenuate the
Aβ-dependent increase in overall protein phospho-tyrosine
levels and active levels of Src and Lyn non-receptor tyro-
sine kinases which correlated with decreased TNFα secre-
tion. In addition to the in vitro analyses, dasatinib was
able to reduce active Src but not Lyn levels as well as
TNFα and microgliosis in the APP/PS1 mice following
28 days of subcutaneous infusion. Our study indicates that
attenuation of specific non-receptor tyrosine kinase activ-
ities, in our case using an FDA approved cancer drug,
dasatinib, may be therapeutically useful as a novel anti-in-
flammatory approach to AD.
Methods
Materials
Anti-Aβ, clones 6E10 and 4G8 were from Covance
(Emeryville, CA, USA). The anti-Lyn antibody, anti-Src,
anti-α-tubulin antibodies, FITC and Texas Red conju-
gated secondary antibodies, and horseradish peroxidase
conjugated secondary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Mouse TNF-α Elisa kit was obtained from R&D Systems
(Minneapolis, MN, USA). Anti-phosphotyrosine (4G10)
antibody was from EMD Millipore (Billerica, MA, USA)
and anti-pLyn (Tyr 396) antibody was purchased from
Abcam (Cambridge, MA, USA). Anti-Iba1 antibody was
from Wako Chemicals USA, Inc (Richmond, VA, USA).
Elite Vectastain ABC avidin and biotin and alkaline
phosphatase kits, biotinylated anti-rabbit, anti-mouse,
and anti-rat antibodies and the Vector VIP and Vector
Blue chromogen kits were from Vector Laboratories Inc.
(Burlingame, CA, USA). Anti-CD68 was obtained from
Serotec (Raleigh, NC, USA). Anti-PSD95 and anti-pSrc
(Tyr416) antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA). Anti-APP antibody
was purchased from Invitrogen (Camarillo, CA, USA).
Synaptophysin and βIII tubulin antibodies were pur-
chased from Chemicon International, Inc (Temecula,
CA, USA). The non-receptor tyrosine kinase inhibitor,
dasatinib, was obtained from LC Laboratories (Woburn,
MA, USA). The transgenic mouse line, strain 005864 B6.
Cg-Tg(APPswe,PSEN1dE9)85Dbo/J and wild type mouse
line, C57BL/6 were obtained from the Jackson Labora-
tory (Bar Habor, ME, USA).
Animal use
All animal use was approved by the University of North
Dakota Institutional Animal Care and Use Committee
(UND IACUC). Mice were provided food and water ad
libitum and housed in a 12 h light:dark cycle. The
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of the National Academies Guide for the Care and Use
of Laboratory Animals (8
th edition).
BV2 cell line
Immortalized murine microglial BV2 cells were obtained
from Dr. Gary E. Landreth, Cleveland, OH, USA. The
cells were maintained at 3×10
6 cells/dish in 100-mm
dishes in DMEM/F12 (Gibco RBL, Rockville, MD, USA)
supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (U.S. Biotechnologies Inc., Parkerford, PA,
USA), 5% horse serum (Equitech-Bio, Inc., Kerrville, TX,
USA), penicillin G (100 units/ml), streptomycin
(100 mg/ml), and L-glutamine (2 mM) and incubated at
37°C in a humidified atmosphere containing 5% CO2 and
95% air.
Murine microglia culture
Microglia were derived, as described previously [53],
from the brains of postnatal day 1 to 3 C57BL/6 J mice.
Briefly, meninges-free cortices were removed, trypsinized
and triturated in microglia media (DMEM/F12 media
containing L-Glutamine (Invitrogen, Carlsbad, CA, USA)
and 20% heat inactivated FBS) and placed in T-75 flasks.
The media in the flasks was replaced completely after
24 h and partially after 7 days with fresh media. The cells
were ready to harvest and count after 14 days.
Cell stimulation
Aβ 1–42 fibrils (American Peptide, Sunnyvale, CA, USA)
were prepared according to an established protocol [54].
Microglia were stimulated by removing them from
growth media into serum-free DMEM/F12 media con-
taining Aβ fibrils. To assess dasatinib effects, BV2 or
microglia were pretreated with the drug for 30 minutes
before Aβ stimulations. For Western blot analyses, five-
minute Aβ stimulations were performed and cells were
lysed using radioimmunoprecipitation assay buffer
(RIPA) (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
Na3VO4 10 mM NaF, 1 mM EDTA, 1 mM EGTA,
0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100,
0.1% SDS, and 0.5% deoxycholate) with protease inhibi-
tors (AEBSF 104 mM, Aprotinin 0.08 mM, Leupeptin
2.1 mM, Bestatin 3.6 mM, Pepstatin A 1.5 mM, E-
64 mM). Protein concentrations were determined using
the Bradford method [55]. For ELISA and toxicity ana-
lyses, cells were stimulated with Aβ for 24 hours. To as-
sess the level of proinflammatory cytokine, TNF-α,
secreted after 24 h stimulation of microglia with Aβ fi-
bril, the media from the cells was collected and analyzed
using a commercially available ELISA kits (R & D Sys-
tems) according to the manufacturer’s protocol. Cell via-
bility was assessed by the MTT reduction assay. After
24-hour stimulation of microglia, media was removed for
ELISA and the cells were incubated with 3[4,5-
dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide
(MTT, 100 μg/mL) for 4 hours. The media was aspirated
and the reduced formazan precipitate was dissolved in
isopropanol. Absorbance values were read at 560/
650 nm via plate reader and averaged +/− SEM.
Western blot analysis of microglia cultures
Lysates from cell stimulation experiments were diluted
into sample buffer and separated via 10% SDS-PAGE,
transferred to polyvinylidene difluoride membrane and
Western blotted using anti-pSrc (Tyr416), anti-pLyn
(Tyr396), Src (loading control) and Lyn (loading control)
and enhanced chemiluminescence for detection (GE
Healthcare, Piscataway, NJ, USA). pSrc/pLyn optical
densities (O.D.) from visualized Western blots were nor-
malized to their respective loading controls (Src/Lyn)
and averaged from five independent experiments.
Collection of brains from different age APP/PS1 mice
Brains from different aged APP/PS1 mice were collected
for longitudinal analyses. 2-, 4-, 6- and 12-month old
transgenic mice (n=5 to 6) along with their age-matched
C57BL/six wild type controls were euthanized and per-
fused with PBS-CaCl2. Brains were rapidly dissected and
divided into left and right hemispheres, with right hemi-
spheres fixed in 4% paraformaldehyde for sectioning.
The left hemispheres were further dissected into differ-
ent brain regions to obtain hippocampus, temporal cor-
tex, frontal cortex and cerebellum, and flash frozen using
liquid N2. The frozen tissue was lysed using RIPA with
protease inhibitors and used for Western blot analysis.
Subcutaneous infusions of dasatinib into APP/PS1 mice
Dasatinib was infused subcutaneously into female APP/
PS1 mouse at 13 months of age. Dasatinib was delivered
via mini-osmotic pumps (model 1004, 0.25 μL/hour de-
livery rate, Alzet, Cupertino, CA, USA). Pumps delivered
either vehicle (DMSO/Hepes) (n=6) or dasatinib
(500 ng/kg/day) (n=7) for 28 days. At the end of the in-
fusion period, mice were euthanized, brains perfused
with PBS-CaCl2 and rapidly collected. Control untreated
APP/PS1 animals were collected at a comparable age of
completion, 14 months. The right hemispheres were col-
lected for fixing in 4% paraformaldehyde and the left
hemispheres were flash frozen in liquid nitrogen for bio-
chemical analysis.
Immunostaining mouse brains
The paraformaldehyde fixed right hemispheres for differ-
ent age mice or from dasatinib treated and control mice
were cut using a freezing microtome. Briefly, paraformal-
dehyde fixed tissue was embedded in a 15% gelatin (in
0.1 M phosphate buffer) matrix and immersed in a 4%
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gelatin matrix. The blocks were then cryoprotected
through three cycles of 30% sucrose for three to four days
each. The blocks were then flash frozen using dry ice/
isomethylpentane, and serial 40 μm sections were cut
using a freezing microtome. Serial sections were used for
immunostaining with anti- pTyr (4G10) antibody at a di-
lution of 1:1,000, anti-Aβ (4G8) and anti-CD68 at a dilu-
tion of 1:500 to 1:1,000, anti-pSrc as 1:250, anti-Iba1 at
1:1,000, and anti-GFAP antibody at a dilution of 1:1,000,
followed by incubation with biotinylated secondary anti-
bodies (1:2,000 dilution) (Vector Laboratories Inc.) and
avidin/biotin solution (Vector ABC kit). The immunor-
eactivity was observed using Vector VIP as chromogen.
For pSrc/CD68 double staining, FITC and Texas Red
conjugated secondary antibodies were used. For phos-
photyrosine/CD68 or Iba1 double-labeling, the sections
were first immunostained with anti-phosphotyrosine
antibody 4G10 using Vector VIP as the chromogen. The
tissue was then incubated in 0.2 N HCl to strip off anti-
bodies then the tissue was double-labeled with either
CD68 or Iba1 using Vector Blue as the chromogen. The
slides were dehydrated and cover slipped using Vecta-
Mount (Vector Laboratories, Inc.) following a standard
dehydrating procedure through a series of ethanol solu-
tions and Histo-Clear (National Diagnostics, Atlanta,
GA, USA). Images were taken using an upright Leica
DM1000 microscope and Leica DF320 digital camera
system (Leica Microsystems Inc., Buffalo Grove, IL,
USA). Figures were made using Adobe Photoshop 7.0
software (Adobe Systems, San Jose, CA). For quantita-
tion purposes, 1.25X images were taken from three con-
secutive serial sections, (960 μm apart) throughout the
hippocampal region. Optical densities from the temporal
cortex or CA1 regions from the same serial sections
were measured using Adobe Photoshop software. All
sections were immunostained simultaneously to
minimize variability and background values in an un-
stained area of tissue for each section were set to zero
using the curve tool before quantifying optical density
values. The optical density of the entire temporal cortex
region/CA1 region from a representative section was
selected via marquee and the same size marquee was ap-
plied to all sections per condition to allow comparison of
optical densities (O.D.) independent of area changes. The
values for each section were averaged (three sections/
brain, five to seven brains per condition) and plotted for
Aβ, immunoreactivity for dasatinib infusion animals,
pSrc immunoreactivities of dastinib treated mice, and Aβ
and CD68 immunoreactivities for longitudinal study ani-
mals. For quantitating phospho-tyrosine immunostaining
from different aged APP/PS1 and wild type mice, the ser-
ial sections were viewed under a microscope and the
number of 4G10 positive plaques were viewed from the
entire CA1 and temporal cortex regions for all the ani-
mals in each condition. The numbers of plaques were
averaged (three sections/brain, five to seven brains per
condition) and plotted. To insure reliability in compari-
son, only immunostains that were processed together
were quantitatively compared to minimize any variability
in staining processing from day-to-day. This allows an
accurate assessment of relative comparisons within par-
allel processed conditions and samples although not ne-
cessarily a reflection of absolute values.
Western blot analyses of mouse brains
Hippocampus and temporal cortex were removed from
flash frozen brains of treated mice, lysed, sonicated in
RIPA buffer and quantitated using the Bradford method
[55]. The lysates were resolved using a custom-built 28-
well comb and 10% SDS-PAGE and transferred to poly-
vinylidene difluoride membranes for Western blotting
using anti-pTyr (4G10), anti-APP, anti-Aβ (6E10), anti-
GFAP, anti-TNF-α and anti-CD68 antibodies with α-
tubulin as their loading control, anti-pSrc (Tyr416), anti-
pLyn (Tyr396) antibodies with anti-Src and anti-Lyn as
their respective loading controls and anti-PSD95 and
anti-synaptophysin with βIII-tubulin as the loading con-
trol. Antibody binding was detected using enhanced
chemiluminescence for detection. Western blots were
quantified using Adobe Photoshop software. Optical
density (O.D.) of bands were normalized against their re-
spective loading controls and averaged (+/−SEM).
T-maze
T-maze analysis was performed as described by Wenk,
1998 [56]. Briefly, upon completion of the in vivo infu-
sion period, control and treated mice were placed into
the starting arm, and the door was raised to allow ani-
mals to walk down the stem and choose an arm. Once
the mice entered an arm with all four feet, they were
returned to the starting arm and the door was closed.
After 30 sec, the door was opened and the mice were
allowed to choose an arm again. The process was
repeated for nine trials with a 30 sec interval between
each trial. The choice of arms was noted each time and
the number of alternations between trials for each mouse
was averaged and plotted.
Statistical analysis
Data are presented as mean +/− standard deviation.
Values statistically different from controls were deter-
mined using one-way ANOVA or Student t-test when
appropriate. The Tukey-Kramer multiple comparisons
post-hoc test was used to determine P-values.
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The non-receptor tyrosine kinase inhibitor, dasatinib,
decreased active-phospho Src levels in microglia BV2 cells
Based upon our prior work demonstrating that both fibril-
lar and oligomeric Aβ stimulate increased non-receptor
tyrosine kinase activity in microglia [38], we determined
whether a brain penetrant tyrosine kinase inhibitor,
dasatinib, could attenuate activity of Src kinase in vitro.
In order to validate the Src-kinase inhibitory ability of
dasatinib, the mouse microglia cell line, BV2, was trea-
ted with varying concentrations of the drug. Dasatinib is
a small molecule ATP-competitive inhibitor of Bcr-Abl
and Src kinase with IC50s for the isolated kinases of
0.55 and 3.0 nM, respectively [57,58]. FDA-approved for
use in cases of chronic phase Philadelphia chromo-
some-positive chronic myelogenous leukemia (CP-
CML), dasatinib (Sprycel, Bristol-Myers Squibb, Prince-
ton, NJ, USA) has been shown to cross the blood-brain
barrier [59]. Although dasatinib will certainly attenuate
c-Abl activity, based upon limited demonstration of c-
Abl in microglia [60] and our prior work demonstrating
robust Aβ-stimulated increase in Src family kinase ac-
tivity [38,41], we expected a major target of dasatinib in-
hibition to be the Src family of non-receptor tyrosine
kinases. As expected, active, phosphorylated Src levels
significantly decreased with increasing dasatinib con-
centrations from 1nM to up 1 μM compared to vehicle
treated BV2 cells (Figure 1). For subsequent treatments
of microglial cells in vitro, a dose of 100 nM dasatinib
was chosen to obtain an optimum effect of Aβ-
dependent tyrosine kinase inhibition in primary
cultures.
Dasatinib attenuated the Aβ-stimulated increase in active-
phospho Src levels in primary murine microglia cultures
In order to determine whether dasatinib was able to re-
duce an Aβ stimulated increase in active tyrosine kinase
levels, primary microglia cultures were treated with Aβ
fibril with or without dasatinib. Microglial cells were pre-
treated with 100 nM dasatinib followed by a five-minute
stimulation by 10 μMA βf to detect changes in the acti-
vated, phosphorylated forms of the specific non-receptor
tyrosine kinases, Src and Lyn. As expected, Aβ fibrils sti-
mulated an increase in active phospho-Src levels com-
pared to vehicle treated cells (Figure 1). The Aβ-
dependent increase in phospho-Src levels was signifi-
cantly attenuated when cells where stimulated in the
presence of dasatinib (Figure 1). Although Aβ fibrils did
not significantly increase the levels of active, phosphory-
lated Lyn kinase at the concentrations used, dasatinib
was still able to significantly reduce levels of active
phospho-Lyn indicating that the drug was not specific
to any particular Src family member (Figure 1). In
addition, the data demonstrated that the Aβ stimulated
increase in microglial active Src kinase levels could be
inhibited using a clinically relevant non-receptor tyro-
sine kinase Src/Abl inhibitor, dasatinib.
Dasatinib attenuated Aβ-stimulated TNF-α secretion in
primary microglia cultures
In order to determine whether the Aβ-stimulated change
in active Src levels was required for changes in pheno-
type, changes in secretion of the pro-inflammatory cyto-
kine, TNF-α, were quantified from the primary microglia
cultures in the presence or absence of dasatinib. Fibrillar
Aβ stimulated a significant increase in TNF-α secretion
compared to control or vehicle treated microglial cells
(Figure 2). This increase in TNF-α secretion was attenu-
ated by 100nM pretreatment of dasatinib with no effect
of cellular viability (Figure 2). The data demonstrated
that inhibition of Src family kinase activity was sufficient
to prevent microglia from acquiring a reactive secretory
phenotype upon Aβ fibril stimulation in vitro.
An age-dependent increase in Aβ plaque density
correlated with microgliosis in a transgenic mouse model
of AD
To determine an appropriate age in vivo for examining
increased tyrosine kinase activity and Aβ-associated
microgliosis, a transgenic APP/PS1 mouse model of AD
was used. Varying age brains of APP/PS1 mice were com-
pared to age-matched controls to validate the use of this
transgenic mouse model for our study. The APP/PS1 mice
were collected at 2, 4, 6 and 12 months of age along with
their age-matched wild type mice (C57BL/6) and brains
were sectioned for histology. Immunostaining demon-
strated a significant increase in APP/PS1 temporal cortex
CD68 immunoreactivity in 6- and 12-month old mice
compared to earlier 2- and 4-month APP/PS1 age groups
and their age-matched C57BL/6 controls (Figure 3). This
increase correlated precisely with increased plaque-asso-
ciated Aβ immunoreactivity in the 6- and 12-month old
APP/PS1 mice (Figure 3). Analyses of hippocampi from all
groups showed similar results to the temporal cortex (data
not shown). These data supported the notion that micro-
glial activation in AD and its mouse models may be a con-
sequence of Aβ fibril interaction. However, to validate an
involvement of tyrosine kinase activity in microglial
phenotype changes during disease, APP/PS1 brains were
next immunostained with anti-phosphotyrosine antibody
as an indirect method to assess overall tyrosine kinase ac-
tivity changes. Immunostaining mouse brains with anti-
phosphotyrosine antibody, 4G10, demonstrated positive
microglial-like as well as vascular immunoreactivity
(Figure 4). Microglial-like immunoreactivity increased in
intensity demonstrating transition from ramified to a
more compact, plaque-clustered morphology with in-
creasing age in APP/PS1 mice compared to controls
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staining as putative microglia demonstrated a trend of
age-associated increase in APP/PS1 temporal cortex
staining with a significant increase by 4 months of age
with significantly higher immunoreactivity at 6 and
12 months (Figure 4). Similar trends were observed in
the hippocampus (data not shown). To validate that
phosphotyrosine immunoreactivity partially co-localized
to microglia, sections were double-labeled with both
antiphosphotyrosine antibody and anti-CD68 or anti-
Iba1 antibodies. Double-labeling demonstrated that a
portion of the phosphotyrosine immunoreactivity
demonstrated clear co-localization with either micro-
glial marker, CD68 or Iba1 (Figure 4). These data con-
firmed that by 12 months of age, this particular
transgenic line had robust phosphotyrosine microglial
reactivity in association with Aβ plaques providing us
with the appropriate time point for use.
Figure 1 Dasatinib dose-dependently attenuated active, phospho-Src kinase levels in the BV2 cell line and primary microglia. (A)
Microglial BV2 cells were vehicle treated (v), or treated with 1 nM, 10 nM, 100 nM and 1 μM dasatinib for 30 minutes. Cells lysates were resolved
by SDS-PAGE and Western blotted using anti-phospho-Src, and Src antibodies. (B) Densitometric analyses of the Western blots were performed
normalizing active-Src levels against their respective Src controls and averaging +/−SEM. Blots are representative of six independent experiments.
Primary microglia were DMSO vehicle treated (veh), or stimulated for 5 minutes with 10 μMA βf in the presence or absence of 30-minute
pretreatment of 100 nM dasatinib. (C) Cells lysates were Western blotted using anti-pSrc or Src (loading control) antibodies and anti-pLyn or Lyn
(loading control) antibodies. A representative blot from six independent experiments is shown. Densitometric analyses of the Western blots was
performed normalizing (D) active, phospho-Src levels against Src controls and (E) active, phospho-Lyn levels against Lyn controls and averaging
+/−SEM. Percent fold changes in phospho-Src and phospho-Lyn levels were plotted. (*P<0.05 vs. vehicle, dasatinib, **P<0.01 vs. Aβ+dasatinib
for pSrc and *P<0.01 vs. Aβ for pLyn).
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Based upon the temporal profiling of microgliosis we
next determined whether inhibition of tyrosine kinase
activity could attenuate the microglial reactivity in this
line. Based upon our in vitro data we hypothesized that
dasatinib treatment would attenuate the Aβ-associated
increase in tyrosine kinase activity, particularly Src, and
subsequent inflammatory changes in the mice. In order
to answer this question, 13 month old APP/PS1 female
mice were subcutaneously infused with dasatinib or ve-
hicle for 28 days. Dasatinib infusion significantly
decreased protein phosphotyrosine levels in the hippo-
campus but not the temporal cortex compared to vehicle
infused control animals (Figure 5). More importantly,
dasatinib infusion significantly decreased levels of active,
phospho-Src in both temporal cortex and hippocampus
compared to control mice (Figure 5). However, dasatinib
infusion had no effect on the active, phosphorylated
levels of the related Src family member, Lyn kinase, dem-
onstrating some specificity of the drug (Figure 5). These
data demonstrated that a subcutaneous route of dasati-
nib delivery was able to inhibit levels of active Src in the
brains of the APP/PS1 mice.
Dasatinib infusion decreased TNF-α levels and
microgliosis in APP/PS1 mice
Based upon the encouraging findings that dasatinib was
able to exert brain effects and decrease active Src
levels, we expected that dasatinib infusion should also
attenuate microgliosis and TNFα secretion as observed
in our in vitro findings. Dasatinib infusion significantly
decreased TNFα levels in both the hippocampus and
temporal cortex correlating with the decrease in active Src
levels and demonstrating a clear brain anti-inflammatory
effect of the drug (Figure 6). Moreover, levels of CD68, the
reactive microglial marker protein, were significantly
decreased in the hippocampus of dasatinib infused brains
but not the temporal cortex. These data demonstrated that
dasatinib inhibition of brain active Src levels correlates
with a significant anti-inflammatory, microglial-inhibitory
effect in APP/PS1 mice. Interestingly, these effects
appeared most robust in the hippocampus compared to
the temporal cortex (Figure 6).
Dasatinib infusion did not alter APP, Aβ, or synaptic
protein levels in APP/PS1 mice
To examine the breadth of changes that might result from
dasatinib infusion we also determined whether adverse
effects on neurons, astrocytes, or Aβ deposition resulted
from drug treatment in addition to the anti-inflammatory,
microglial-inhibitory changes. However, dasatinib admin-
istration had no effect on either total APP levels or Aβ
levels in the hippocampus or temporal cortex of treated
mice compared to vehicle controls (Figure 7). In addition,
dasatinib treatments did not increase levels of the react-
ive astrocyte marker protein, GFAP, in the infused ani-
mals compared to vehicle control mice (Figure 7).
Finally, dasatinib treatment did not have any significant
effects on levels of either presynaptic, synaptophysin, or
post-synaptic, PSD 95, proteins in either the temporal
cortex or hippocampus compared to vehicle treated mice
(Figure 7). These data demonstrated that the Src inhibi-
tory, anti-inflammatory, microglia-inhibitory effects of
dasatinib treatment did not correlate with any robust ad-
verse effects such as increased astrogliosis, neuron or
synaptic loss, and increased Aβ deposition.
Dasatinib infusion decreased immunoreactivity of protein
phosphotyrosine, phospho-Src and CD68 in APP/PS1 mice
To provide qualitative assessments along with the quan-
titative Western blot analyses, select immunohistochem-
ical studies were also performed from the treated
Figure 2 Dasatinib attenuated Aβ1-42 stimulated-microglial
secretion of the proinflammatory cytokine, TNF-α. Primary
microglia were unstimulated (control), DMSO vehicle treated (veh),
or stimulated for 24 hours with 10 μMA βf in the presence/absence
of 100 nM dasatinib. (A) Media was collected from treated cells and
used to quantify changes in TNF-α secretion via ELISA. Secreted
values were averaged +/−SEM. (B) After media removal, the treated
cells were used to assess cell viability via the MTT reduction assay.
Absorbance values (560/650 nm) were averaged+/−SEM. (**P<0.01
from control, ***P<0.001 vs. vehicle, dasatinib and Aβ+dasatinib).
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noreactivity in dasatinib infused mouse brains appeared
dramatically less than vehicle treated mice in both the
hippocampus and temporal cortex (Figure 8). A similar
trend of dasatinib decreased immunoreactivity was
observed for active phospho-Src versus vehicle controls
(Figure 8). Similar to phosphotyrosine, pSrc immunor-
eactivity also localized to vasculature as well as micro-
glial-like immunoreactivity (Figure 8). Double-labelling
verified that a portion of the pSrc immunoreactivity co-
localized to microglia (Figure 8). Because the majority of
pSrc immunoreactivity was observed in plaque-associated
microglial-like cells we suggest that the significant
decreases in active Src and phosphotyrosine levels
observed by Western blot analyses were a reflection of
microglial changes due to the drug. However, certainly a
portion of both phosphotyrosine and pSrc level changes
detected by the Western blot analyses is due to contribu-
tions from cells other than microglia. Also as predicted,
levels of CD68 reactive microglial immunoreactivity in
dasatinib infused mice was noticeably decreased com-
pared to vehicle treated mice in both the hippocampus
Figure 3 Microgliosis in the APP/PS1 model of AD positively correlated with increased Aβ plaque density with age. Serial coronal
sections from 2- , 4- , 6- and 12-month old controls (C57BL/6) and age-matched transgenic animals (APP/PS1) (n=5 to 6) were immunostained
for (A) activated microglia (anti-CD68) and Aβ (anti-4G8 antibody). Representative hemi-sections are shown with select high magnification fields.
(B) Immunoreactivity densities from the temporal cortex region for CD68 and 4G8 were quantified, averaged and graphed (+/−SEM) for *P<0.001
from 2- and 4-month APP/PS1 animals,
#P<0.001 from 2-, 4-, 6- and12-month wild type animals for CD68,
#P<0.001 from 2-, 4- and 6-month wild
type mice for 4 G8, and
$P<0.001 from 6-month APP/PS1 animals.
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http://www.jneuroinflammation.com/content/9/1/117and temporal cortex (Figure 8). Consistent with the
Western blot analysis, GFAP immunoreactivity for react-
ive astrocytes was not visually different between dasatinib
and vehicle infused mice in either temporal cortex or
hippocampus (Figure 8). The qualitative immunostaining
findings corroborated the quantitative Western blot ana-
lyses and suggest that the significant decreases in pSrc
levels were largely due to decreased microglial immunor-
eactivity, our intended target for the drug.
Aβ plaque load was not affected by dasatinib infusions
into the APP/PS1 mice
One possible consequence of attenuated tyrosine kinase
activity in microglia could be inhibition of phagocytic
ability. It is well known, for instance, that tyrosine kinase
activity can affect macrophage phagocytic ability [61-63].
Therefore, inhibition of Src or related kinase activity
might attenuate any ability microglia have to clear Aβ
deposits in the brain producing an unwanted side-effect
of increased plaque load. Based upon the Western blot
analysis, dasatinib treatment had no effect on altering
APP or Aβ levels in the brains of mice (Figure 8). How-
ever, to better assess whether the drug had any effects on
insoluble fibrillar deposits in the brain, quantitative
immunostaining of Aβ plaques was performed. Dasatinib
treatment had no effect on plaque load in treated mice
compared to vehicle controls in either the hippocampus
or temporal cortex (Figure 9). These data demonstrate
that the microglial-inhibitory effects of dasatinib do not
result in unwanted effects of increasing Aβ deposition or
accumulation.
Dasatinib infusion improved T maze performance in
APP/PS1 mice
Although there was no effect of dasatinib treatment on
Aβ deposition, the clear and somewhat specific effect of
Src inhibition correlating with anti-inflammatory, micro-
glial-inhibitory effects provided an opportunity to assess
Figure 4 Plaque-associated microglial phosphotyrosine immunoreactivity increased with age in APP/PS1 mice. (A) Serial coronal sections
from 2-, 4-, 6-and 12-month-old controls (C57BL/6) and age-matched transgenic animals (APP/PS1) (n=5 to 6) were immunostained with anti-
phosphotyrosine antibody (4G10). Representative select high magnification fields from the temporal cortex of hemisections are presented. (B)T o
validate microglial co-localization of phospho-tyrosine immunoreactivity, 12-month APP/PS1 sections were double-labeled using anti-
phosphotyrosine antibodies and VIP as the chromogen (black arrows) and anti-CD68 or Iba1 and Vector Blue as the chromogen (green arrows).
Double-labeled cells are indicated with yellow arrows. (C) To quantify immunoreactivity and omit the inclusion of non-microglial phosphotyrosine
immunoreactivity, 4G10 positive plaques from APP/PS1 mice were counted from the temporal cortex and averaged and graphed (+/−SEM) for
*P<0.001 from two-month APP/PS1 mice,
#P<0.001 from two-month and four-month APP/PS1 animals,
$P<0.001 from four- and six-month APP/
PS1 animals.
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ment to the mice. After treatments, spontaneous alterna-
tions from dasatinib treated, vehicle treated and control
animals were quantified during T maze analyses. This
particular model of spatial memory was selected based
upon its sensitivity of detection of cognitive deficit in
AD mouse models [64] and its preference for detecting
changes in hippocampal-based performance differences
[65,66] since our most significant effects of drug were
observed in the hippocampus. Dasatinib infused animals
demonstrated improved cognitive performance repre-
sented by a significant increase in spontaneous alterna-
tions compared to vehicle treated mice (Figure 10).
These data validated that subcutaneous administration of
the Src/Abl tyrosine kinase inhibitor, dasatinib, is able to
provide cognitive enhancing effects to APP/PS1 mice
while attenuating microglial activation and proinflamma-
tory cytokine, TNFα, levels in the brain.
Discussion
Our findings demonstrated that Aβ fibrils stimulate
microglia activation in vitro via a non-receptor tyrosine
kinase, Src, associated pathway that results in increased
secretion of the proinflammatory cytokine, TNF-α.I t
was possible to attenuate the Aβ-stimulated microglial
phenotype change using a dual Src/Abl inhibitor, dasati-
nib. The in vitro observations were validated in vivo
demonstrating that subcutaneous infusion of dasatinib
into 13 month old APP/PS1 transgenic mice attenuated
overall tyrosine phosphorylation and active Src levels, in
particular, in the hippocampus. The drug did not affect
Aβ plaque load but reduced microgliosis and TNF-α
levels in these animals without altering synaptic markers
in neurons. Moreover, dasatinib provided a significant in-
crease in cognitive performance in correlation with this
anti-inflammatory action. Collectively, these findings
support the idea that Aβ fibrils can serve as a microglial
activating ligand in disease contributing to their proin-
flammatory phenotype and use of selective non-receptor
tyrosine kinase inhibitors is an effective strategy to limit
microglial-mediated changes during disease.
Although it has been suggested that Aβ-stimulated
microglial activation contributes to the pathophysiology
of AD [24-26,28-30,33,67] and a broad range of micro-
glial secreted inflammatory markers are elevated in AD
brains, including IL-1α, IL-1β, TGF-β and TNF-α
[68,69], enthusiasm for an anti-inflammatory approach
to treating AD has decreased, in part, due to lack of drug
efficacy of a number of human trials that targeted
cyclooxygenase (Cox) activity in AD patients [70-74]. In-
deed, Cox inhibition during later stages of disease had
adverse effects and only demonstrated protection when
administered long-term to asymptomatic individuals
[37]. One possibility for the lack of efficacy of Cox
Figure 5 Dasatinib infusion reduced protein phospho-tyrosine and active phospho-Src kinase levels in APP/PS1 brains. Vehicle or
dasatinib (500 ng/kg/day) was infused subcutaneously into 13-month-old APP/PS1 for 28 days (n=7). Hippocampus and temporal cortex regions
were dissected from the left hemispheres and resolved by 10% SDS-PAGE and Western blotted. (A) Hippocampal and (B) temporal cortex brain
lysates from control (14-month APP/PS1), vehicle infused, and dasatinib infused animals were blotted using anti-phosphotyrosine, pTyr (4G10),
pSrc, pLyn, α-tubulin, Src, and Lyn antibodies. Optical densities were averaged and graphed (+/−SEM) from blots of (C) hippocampus (*P<0.05
from controls, ***P<0.001 from vehicle) and (D) temporal cortex. (*P<0.05 from controls).
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http://www.jneuroinflammation.com/content/9/1/117inhibitors is the fact that Cox enzymes are expressed by
multiple cell types in the brain and general drug inhib-
ition has no cellular selectivity. Another possibility for
the failed efficacy is that Cox 1 or 2 enzyme activities are
simply not relevant targets for attenuating microglia-
dependent changes. For this reason we focused on the
direct signaling response initiated in microglia upon Aβ
fibril stimulation. It has been reported from both AD
brains [75-77] and mouse models [13,78] that elevated
protein phosphotyrosine levels are reliable markers of re-
active microglia associated with plaques. In vitro studies
using monocytic lineage cells [24,44,47] and microglia
[38,41] have supported these data by demonstrating that
fibrillar Aβ stimulates a specific increase in overall pro-
tein tyrosine phosphorylation. Based upon our in vitro
data, we targeted Src as a key enzyme activated down-
stream of Aβ fibril stimulation and demonstrated that a
clinically available drug, dasatinib, was able to improve
cognitive function while attenuating microglial activation
and active Src levels in these cells. Importantly, this anti-
inflammatory effect did not adversely affect Aβ plaque
load in the mice. Therefore, a directed anti-inflammatory
strategy targeting the particular enzymes involved in Aβ-
stimulated microgliosis may be more relevant than
broad-based Cox inhibition for testing during disease.
Moreover, the fact that this tyrosine kinase inhibition
strategy was effective even during advanced stages of dis-
ease in the mice suggests that this particular form of
anti-inflammatory therapy is viable during advanced dis-
ease in contrast to Cox inhibition.
We are aware that the effect of decreasing microglial
active Src and brain TNFα levels does not necessarily
prove that these changes were responsible for the
improved cognitive performance. However, our in vitro
data clearly demonstrated that dasatinib treatment and
Src inhibition led to attenuated TNFα secretion provid-
ing correlative evidence that Src inhibition in microglia
in vivo contributed to the decrease in TNFα observed.
Moreover, recent human data using TNFα neutralizing
drugs demonstrated cognitive improvement in AD
patients [79] suggesting that diminished TNFα levels in
the mice could have contributed to the cognitive
improvements observed.
We also appreciate that dasatinib treatment may affect
a number of other kinases in vitro and in vivo, and nu-
merous cells express Src family kinases and Abl. Non-
receptor Src family tyrosine kinases are expressed widely
in the mammalian CNS and are known to play a role in
proliferation and differentiation of the CNS [80-89]. In-
deed, Src family kinase activities are crucial for synaptic
plasticity, including learning and memory [90-94]. Add-
itionally, there is compelling evidence that neuronal Abl
activity can also mediate microgliosis in vivo, suggesting
that dasatinib may also work through this mechanism to
exert its anti-inflammatory effects [60]. It is also intri-
guing that Abl is able to phosphorylate tau protein on
Figure 6 Dasatinib infusion reduced CD68 and TNF-α protein levels in APP/PS1 brains. (A) Hippocampal and (B) temporal cortex brain
lysates from control, vehicle, and dasatinib infused animals were Western blotted for activated microglia using anti-CD68 antibody and anti-pro-
inflammatory cytokine TNF-α antibody along with anti-α-tubulin as a loading control. Optical densities were averaged and graphed (+/−SEM)
from blots of (C) hippocampus (**P<0.01 from controls) and (D) temporal cortex (*P<0.05 from controls).
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http://www.jneuroinflammation.com/content/9/1/117Tyr 394 identified from AD brains as well as the intra-
cellular domain of APP to modulate signaling responses
[95-97]. Although we have not focused on Abl expres-
sion or activity in this study we appreciate that activity
of this kinase is of great interest to not only the field of
AD but myriad conditions in which oxidative stress-
associated neuron death is involved, including Parkin-
son’s disease [60,96,98-102]. However, this interest in
Abl activity to regulate cell death [60], parkin phosphor-
ylation [99,100] and tau phosphorylation [98,101,102] is
all based upon neuronal expression of the kinase. In-
deed, there is no reported expression of Abl in micro-
glia, to the best of our knowledge. We expect that
dasatinib actions in the brain will certainly include in-
hibition of not only microglial Src activity but additional
Src family members expressed in microglia and other
cells as well as Abl, which will have a broader target
base than only a single kinase activity in microglia. This
may have additional therapeutic benefits of not only
anti-inflammatory actions on microglia but also direct
neuroprotection. We do not rule out that some of the
changes we observed are not also due to inhibition of
Src family kinases or other non-receptor kinases, includ-
ing Abl in our experiments. Certainly, our staining
demonstrated additional vasculature phospho-tyrosine
and pSrc immunoreactivity outside of the microglial
immunoreactivity. Therefore, any strategy to manipulate
activity of these tyrosine kinases in the brain should be
carefully considered with regard to particular cellular
targets. By focusing on microglia-Aβ interaction and
demonstrating specificity of dasatinib for Src versus the
related family member Lyn in vivo as well as a clear im-
provement in cognitive performance, we suggest that
reagents, such as dasatinib, at least be considered for
anti-inflammatory human testing but, more importantly,
for further drug development.
Figure 7 Dasatinib infusion did not alter levels of APP, Aβ, synaptophysin, PSD95, or GFAP levels in APP/PS1 brains. (A) Hippocampal
and (B) temporal cortex brain lysates from control, vehicle, and dasatinib infused animals were used for Western blot analyses using anti-Aβ clone
6E10 antibody, anti-APP, anti-synaptophysin, anti-PSD95, anti-GFAP, anti-α-tubulin and βIII tubulin (loading control) antibodies. Optical densities for
each antibody were normalized to tubulin loading controls, averaged, and graphed (+/−SEM) for (C) hippocampus and (D) temporal cortex.
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http://www.jneuroinflammation.com/content/9/1/117Figure 8 Dasatinib infusion attenuated microgliosis, protein phosphotyrosine and active phospho-Src immunoreactivity with no effect
on GFAP immunoreactivity in APP/PS1 brains. Right hemispheres from brains of dasatinib infused, vehicle infused and APP/PS1 controls
animals were fixed, serially sectioned and immunostained using (A) anti-phosphotyrosine (4 G10), anti-CD68, anti-GFAP, and anti-phospho-Src
(pSrc) antibodies. Representative images from the CA1 region of the hippocampus (HP) as well as the temporal cortex (TC) are shown with select
high magnification TC fields. (B) High magnification images of pSrc immunoreactivities from control APP/PS1 temporal cortex and hippocampus
demonstrate robust plaque-associated immunoreactivity (arrow) along with vascular immunoreactivity (arrow). (C) Fluorescent double-labeling of
control APP/PS1 brains demonstrated clear pSrc (red) immunoreactivity co-localizing with CD68 (green) staining. (D). Relative levels of pSrc
immunoreactivity in the temporal cortex were quantified from serial stained sections from vehicle and dasatinib infused brains, averaged
(+/−SEM), and graphed (***P<0.001 via student’st-test).
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13 months of age with established plaques and reactive
microglia to test the efficacy of our anti-inflammatory
strategy in late-stage disease. However, it will be import-
ant in future work to determine if a strategy of kinase in-
hibition can attenuate or delay behavioral decline or
microgliosis in earlier stage disease. Although our
longitudinal assessment in these mice suggested that
phosphotyrosine immunoreactive microglia correlated
with increased plaque deposition, we have observed in
earlier work that soluble oligomeric forms of Aβ are also
potent stimuli of microglia responsible for initiating a
unique type of tyrosine kinase-based signaling response
[38]. Therefore, fully determining the specific signaling
pathways involved in different forms of Aβ stimulation
of microglia may offer a strategy for inhibiting specific
tyrosine kinase activities at different disease time points
to maximally produce anti-inflammatory effects.
Conclusions
These data demonstrate that the mechanism underlying
amyloid-dependent microgliosis in AD may involve
increased Src family kinase activity. We targeted this
specific signaling response with dasatinib, a dual Src/Abl
inhibitor used for treatment of chronic myeloid leukemia
[103,104] For the first time, we have found that dasatinib
treatment not only attenuated microgliosis, TNFα levels,
and active Src levels in the brains of APP/PS1 mice but
also improved cognitive performance. This suggests that
targeting the specific enzymes involved in Aβ-stimulated
microglial activation may be efficacious therapeutically
even during late stages of disease.
AD, Alzheimer’s Disease; Aβ, amyloid beta; APP, amyl-
oid precursor protein; GFAP, glial fibrillary acidic pro-
tein; Iba1, ionized calcium binding adaptor molecule 1;
Figure 9 Dasatinib infusion did not affect Aβ plaque load in the brains of APP/PS1 mice. Serial sections of right hemispheres from brains of
dasatinib infused, vehicle infused, and control APP/PS1 mice were immunostained using anti-Aβ antibody (clone 4 G8) and plaque load was
quantified. (A) Representative images of the temporal cortex (TC) and hippocampus (HP) from brain hemispheres are shown with select high
magnification TC fields. (B) Mean optical density measurements from the CA1 region of the hippocampus as well as the temporal cortex are
shown +/− SEM.
Figure 10 Dasatinib infused APP/PS1 mice demonstrated
increased spontaneous alternations during T maze testing.
Control untreated 14-month APP/PS1 mice, dasatinib infused mice
or vehicle infused controls (n=7) were used for T maze testing on
Day 29 following 28 days of drug or vehicle infusion. The mean
number of spontaneous alternations +/− SEM per treatment group
were graphed. (*P<0.05 vs. control, ***P<0.001 vs. vehicle).
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necrosis factor α.
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